Recent Updates
Recently added Catalysts
PODD Positive Sentiment

Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum

Friday, September 18, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Insulet Corporation announced its participation in the Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum scheduled for September 24, 2026. The event will feature a presentation by management at 12:30 p.m. ET, with a live webcast available for investors. This participation underscores Insulet's leadership in the insulin pump market.

Market Sentiment Analysis

POSITIVE FACTORS

  • Insulet is recognized as a leader in insulin pump technology.
  • Participation in a prominent healthcare forum highlights company visibility.
  • Management's engagement with investors reflects confidence in future growth.

Full Press Release Details

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum on Thursday, September 24, 2026, at 12:30 p.m. (Eastern Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About

Frequently Asked Questions

When will Insulet present at the Bernstein forum?

Insulet will present on September 24, 2026, at 12:30 p.m. ET.

Where can I watch the Insulet presentation?

The presentation will be available via live webcast on Insulet's Investor Relations website.

What is the focus of the Bernstein Healthcare Forum?

The forum highlights leaders and disruptors in the healthcare sector.

What technology does Insulet specialize in?

Insulet specializes in tubeless insulin pump technology with its Omnipod brand.

ShareAdd on Google
Tags: PODD Viatris Investor Conferences Healthcare Insulet healthcare forum insulin pump technology Bernstein Insights
Last updated: Sep 18, 2026

Biotech snapshot

Cash runway
$535M liquidity · $0M/mo burn
Low dilution risk